Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: J Thorac Oncol. 2013 Mar;8(3):270–278. doi: 10.1097/JTO.0b013e31827d525c

Figure 4. In vitro effects of erlotinib, fulvestrant or the combination of both agents on EGFR-TKI resistant, EGFR-mutant lung cancer cell proliferation and viability.

Figure 4

Figure 4

Growth curves of the H1975 line after 6 days of treatment with erlotinib (diamonds), fulvestrant (squares), or the combination of the two drugs (triangles) are shown at the concentrations listed. Combination index (CI) for the combination at constant ratio is shown (A). Apoptosis at 72 hours (B) was assessed in H1975 cells with no therapy (white), erlotinib 1 µM (stripes), fulvestrant 200 nM (black) or the combination (checked). Error bars indicate standard error based on duplicate experiments.